CorVista Health, Inc.

Based in Canada, CorVista Health, Inc. operates as a medical technology company focused on developing innovative diagnostic solutions for cardiovascular health, including the use of advanced machine learning algorithms for rapid assessments of coronary artery disease and pulmonary hypertension. CorVista Health, Inc. was founded in 2012 in Toronto, Canada, and specializes in point-of-care diagnostic technologies.

The company has secured funding through 5 deals, with the most recent occurring on March 4, 2021, when it raised USD 65 mn in a Series C round led by Ambix Ventures, alongside participation from MedVenture Partners. The company has not reported any changes in operational strategy or structure over its history. Don Crawford serves as the CEO. CorVista Health primarily offers the CorVista System®, a groundbreaking point-of-care diagnostic platform designed to evaluate significant coronary artery disease (CAD) and pulmonary hypertension (PH) during a single patient visit.

This non-invasive system utilizes advanced machine learning algorithms to provide rapid and accurate diagnostic results, addressing critical issues in cardiovascular healthcare. The system is employed in various healthcare settings, including hospitals, outpatient clinics, and cardiology practices, primarily within the U. S. market and has been introduced to international markets such as Saudi Arabia through strategic partnerships.

Healthcare providers, physicians, and patients are the end users of this technology, benefiting from timely and accurate heart health assessments. CorVista Health generates revenue through direct sales of the CorVista System® to healthcare facilities and providers. The business model focuses on B2B transactions, collaborating with hospitals and clinics to implement its diagnostic solutions. This includes the sale of the diagnostic platform and potential service agreements for ongoing support.

Specific pricing plans for the CorVista System® have not been disclosed, but the offering serves as a pivotal tool for improving patient care in cardiovascular diagnostics. In March 2021, CorVista Health, Inc. raised USD 65 mn in Series C funding, which will be utilized to accelerate product development for the CorVista System and scale its infrastructure ahead of commercialization. The company plans to expand its presence in new markets, with a focus on enhancing its reach in the U.

S. and exploring opportunities in international regions. Don Crawford will continue as CEO, guiding these initiatives as the company seeks to enhance its product offerings and market footprint.